Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan

被引：0
|
作者：
Xiuting Mo
Kensuke Moriwaki
Kosuke Morimoto
Kojiro Shimozuma
机构：
[1] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
[2] Kyoto University,Graduate School of Medicine
[3] Ritsumeikan University,Division of Health Services Research, Department of Biomedical Sciences, College of Life Sciences
[4] Ritsumeikan University,Comprehensive Unit for Health Economic Evidence Review and Decision Support (CHEERS), Research Organization of Science and Technology
来源：
Clinical Drug Investigation | 2022年 / 42卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 609
页数：10
相关论文
共 50 条
  • [31] Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott
    Rizvi, Naiyer A.
    Chow, Laura Q.
    Borghaei, Hossein
    Brahmer, Julie
    Ready, Neal
    Gerber, David E.
    Shepherd, Frances A.
    Antonia, Scott
    Goldman, JonathanW.
    Juergens, Rosalyn A.
    Laurie, Scott A.
    Nathan, Faith E.
    Shen, Yun
    Harbison, Christopher T.
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2980 - +
  • [32] Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
    Borghaei, H.
    Ciuleanu, T. -E.
    Lee, J. -S
    Pluzanski, A.
    Caro, R. Bernabe
    Gutierrez, M.
    Ohe, Y.
    Nishio, M.
    Goldman, J.
    Ready, N.
    Spigel, D. R.
    Ramalingam, S. S.
    Paz-Ares, L. G.
    Gainor, J. F.
    Ahmed, S.
    Reck, M.
    Maio, M.
    O'Byrne, K. J.
    Memaj, A.
    Nathan, F.
    Tran, P.
    Hellmann, M. D.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2023, 34 (02) : 173 - 185
  • [33] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [34] Topotecan active as first-line combination therapy for advanced non-small-cell lung cancer
    不详
    ONCOLOGY-NEW YORK, 2001, 15 (02): : 186 - +
  • [35] The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
    Lu, Tingting
    Huang, Yufan
    Cai, Zhongjie
    Lin, Wangchun
    Chen, Xiaoxiao
    Chen, Ruijia
    Hu, Yingying
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [36] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [37] Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
    Shang, Fangjian
    Zhang, Boyuan
    Kang, Shuo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (03) : 337 - 343
  • [38] Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
    Kashiwa, Munenobu
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024, 25 (03): : 459 - 470
  • [39] Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan
    Munenobu Kashiwa
    The European Journal of Health Economics, 2024, 25 : 459 - 470
  • [40] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
12345